Clinical Trial Update: Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing tolerability of repeat intracerebroventricular administration of sNN0031 infusion solution in Parkinson's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• sNN0031 infusion solution

Snippet

Sponsor: Newron Sweden AB | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: TERMINATED